M&A in China’s healthcare industry stays active in 2016

By Ding Yining | March 27, 2017, Monday |

Online Edition

CHINA’S healthcare industry, including drug, pharmaceutical facilities, and medical services sectors, has seen the size of its merge and acquisition reach US$36.2 billion, contributing 5 percent to the total M&A market in China, PwC said in a release today.

Drug manufacturing sector delivered 301 cases of M&A in 2016, the biggest in number and contributing 49 percent of the overall M&A cases.

M&A transactions reached a record high in 2015 and the sentiment remained fervent in 2016, according to the release.

It expected healthcare service to receive continuous attention this year, with the aging population and huge demand for healthcare services at all levels.

"Large pharmaceutical groups and especially listed companies are seeking to expand their market size and will likely speed up their merge and acquisition pace and drug retailers would also seek to beef up their online presence," the report says.

Business

About Us
|
Terms of Use
|
RSS
|
Privacy Policy
|
Contact Us
|
Shanghai Call Center: 962288
|
Tip-off hotline: 52920043

沪ICP证：沪ICP备05050403号-1
|
互联网新闻信息服务许可证：31120180004
|
网络视听许可证：0909346
|
广播电视节目制作许可证：沪字第354号
|
增值电信业务经营许可证：沪B2-20120012

M&A in China’s healthcare industry stays active in 2016

Email this to your friend